Placebo Cohorts in Phase-3 MS Treatment Trials – Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data

• Jan-Patrick Stellmann ,

  * E-mail: j.stellmann@uke.uni-hamburg.de

  Affiliation Institute for Neuroimmunology and Clinical MS Research (inims) and Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Anneke Neuhaus,

  Affiliation Sylvia Lawry Centre for Multiple Sclerosis Research, Munich, Germany

  ⨯
• Lena Herich,

  Affiliation Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Sven Schippling,

  Affiliation Neurology Clinic, Department of Clinical Neuroimmunology and Multiple Sclerosis Research, University Medical Center Zürich, Zürich, Switzerland

  ⨯
• Matthias Roeckel,

  Affiliation Teva Pharma GmbH, Ulm/Mörfelden-Walldorf, Germany

  ⨯
• Martin Daumer,

  Affiliation Sylvia Lawry Centre for Multiple Sclerosis Research, Munich, Germany

  ⨯
• Roland Martin,

  Affiliation Neurology Clinic, Department of Clinical Neuroimmunology and Multiple Sclerosis Research, University Medical Center Zürich, Zürich, Switzerland

  ⨯
• Christoph Heesen

  Affiliation Institute for Neuroimmunology and Clinical MS Research (inims) and Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯